LL-37 (Cathelicidin) vs Teriparatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →Side-by-Side Comparison
| Aspect | LL-37 (Cathelicidin) | Teriparatide |
|---|---|---|
| Dose Range | 500 mcg–1.6 mg | 20 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 2–4 weeks | 52–104 weeks |
| Route | topical | subcutaneous |
| Mechanism | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. |
| Typical Dosage | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. |
| Administration | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. |
| Side Effects | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. |
| Best For |
What They Have in Common
LL-37 (Cathelicidin), Teriparatide are both commonly used for:
Which Has Stronger Evidence?
- Recovery & Healing: Teriparatide has stronger research support.
| Goal | LL-37 (Cathelicidin) | Teriparatide |
|---|---|---|
| Recovery & Healing | medium | high |
Key Studies
LL-37 (Cathelicidin)
- Cathelicidin LL-37 Expression in Human Breast Implant Capsules.
Plastic and reconstructive surgery, 2024
- Salivary Cathelicidin (LL-37) in Children and Adolescents Living with HIV.
Biomedicine hub, 2024
- Antifungal properties of cathelicidin LL-37: current knowledge and future research directions.
World journal of microbiology & biotechnology, 2023
Teriparatide
- Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.
JAMA, 2026
- The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis.
The Journal of clinical endocrinology and metabolism, 2025
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis.
Journal of bone and mineral metabolism, 2025
Ready to Learn More?
Looking for trusted sources?